Silver Book Fact

A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took alendronate. The study followed about 1,200 women with low bone mass for over a year.

Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate. http://www.rheumatology.org/press/2008/2008_press_14.asp. Published October 2008

Reference

Title
Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate
Publication Date
Published October 2008
Authors
Deal, Chad, Jacques Brown, Robert Recker, Richard Prince, Douglas Kiel, Jose Ã?lvaro-Gracia, Luiz de Gregorio, Peyman Hadji, Lorenz Hofbauer, Huei Wang, Matthew Austin, Richard Newmark, Cesar Libanati, Rachel Wagman, Javier San Martin, Henry Bone
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Patients with vertebral fractures who underwent kyphoplasty, a procedure that stabilizes fractures of the spine, were found in one study to have reduced pain, fewer new fractures, and less healthcare…  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.